# Modifiable Risk Factors in Atrial Fibrillation: Clinical Implications and Pathophysiological Insights

**Authors:** Chamath Jagoda

PMC · DOI: 10.1111/anec.70171 · Annals of Noninvasive Electrocardiology · 2026-03-02

## TL;DR

This paper reviews how lifestyle and health factors like obesity and sleep apnea contribute to atrial fibrillation and how managing them can improve treatment outcomes.

## Contribution

The paper provides a synthesis of how modifiable risk factors converge on shared atrial mechanisms to promote AF and how targeting them improves clinical outcomes.

## Key findings

- Weight loss and CPAP therapy can reverse atrial remodeling and reduce AF recurrence.
- Hypertension and diabetes contribute to AF through fibrosis and autonomic imbalance.
- Cardiorespiratory fitness has a U-shaped relationship with AF risk, with moderate exercise being protective.

## Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide, and its growing prevalence is increasingly driven by modifiable lifestyle and clinical factors. Understanding how obesity, hypertension, diabetes, obstructive sleep apnoea (OSA), alcohol intake, and cardiorespiratory fitness each contribute to AF onset, progression, and recurrence is essential for developing comprehensive prevention and treatment strategies.

We performed a narrative review of the available literature assessing six key modifiable risk factors for AF. Evidence was synthesized regarding each factor's pathophysiological effects on atrial structure and electrophysiology, as well as the impact of targeted interventions on arrhythmia burden and procedural outcomes.

Every 1 kg/m2 increase in body mass index (BMI) raises AF risk by 50%, with sustained weight loss reversing atrial remodeling and improving arrhythmia‐free survival. Hypertension increases atrial pressure, electrical heterogeneity, and fibrosis; resistant cases may benefit from adjunctive renal denervation. Diabetes promotes oxidative stress, profibrotic signaling, and autonomic neuropathy, reducing cardioversion success and antiarrhythmic efficacy. OSA induces intermittent hypoxia and sympathetic surges, destabilizing atrial substrates; CPAP therapy reduces remodeling and halves recurrence after cardioversion or ablation. Alcohol exerts dose‐dependent ion‐channel alterations, structural changes, and autonomic disruption. Cardiorespiratory fitness shows a U‐shaped relationship: moderate exercise is protective, whereas endurance extremes and inactivity foster atrial stretch, fibrosis, and ectopic triggers. Across all factors, shared mechanisms of fibrosis, inflammation, and autonomic imbalance emerge as key therapeutic targets.

Integrating risk‐factor modification into AF rhythm‐control protocols addresses fundamental disease mechanisms and enhances procedural efficacy, offering clinicians a framework for prevention and therapy.

Modifiable cardiometabolic and lifestyle factors converge on shared atrial mechanisms, including fibrosis, autonomic imbalance, and electrical remodeling, to promote AF initiation and recurrence. Targeting these upstream drivers through structured risk‐factor management enhances rhythm‐control durability and improves long‐term clinical outcomes.

## Linked entities

- **Diseases:** atrial fibrillation (MONDO:0004981), diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** CHI3L1 (chitinase 3 like 1) [NCBI Gene 1116] {aka ASRT7, CGP-39, GP-39, GP39, HC-gp39, HCGP-3P}, RYR2 (ryanodine receptor 2) [NCBI Gene 6262] {aka ARVC2, ARVD2, RYR-2, RyR, VACRDS, VTSIP}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, TIMP1 (TIMP metallopeptidase inhibitor 1) [NCBI Gene 7076] {aka CLGI, EPA, EPO, HCI, TIMP, TIMP-1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, GJA5 (gap junction protein alpha 5) [NCBI Gene 2702] {aka ATFB11, CX40}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, HSPB1 (heat shock protein family B (small) member 1) [NCBI Gene 3315] {aka CMT2F, HEL-S-102, HMN2B, HMND3, HS.76067, HSP27}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, C1QL1 (complement C1q like 1) [NCBI Gene 10882] {aka C1QRF, C1QTNF14, CRF, CTRP14}
- **Diseases:** Apnoea (MESH:D001049), Atherosclerosis (MESH:D050197), CSA (MESH:D020182), BS (MESH:D000267), Hypertension (MESH:D006973), left ventricular hypertrophy (MESH:D017379), Symptom (MESH:D012816), Excessive daytime sleepiness (MESH:D006970), Weight Loss (MESH:D015431), re-entrant arrhythmias (MESH:D013611), AF (MESH:D001281), Alcohol Abstinence (MESH:D009357), cardiovascular disease (MESH:D002318), diabetic autonomic neuropathy (MESH:D003929), dilation (MESH:D002311), atrial ectopy (MESH:D050030), myocardial infarction (MESH:D009203), Cardiac autonomic neuropathy (MESH:D006331), pulmonary-vein and ventricular ectopy (MESH:D000071078), cardiac remodeling (MESH:D020257), adiposity (MESH:D018205), heart failure (MESH:D006333), atrial dilatation (MESH:C563984), T2DM (MESH:D003924), OSA (MESH:D020181), left atrial enlargement (MESH:D059446), autonomic neuropathy (MESH:D009422), Hypopnea (MESH:D012891), coronary disease (MESH:D003327), Atrial Remodeling (MESH:D064752), Sleep Disorders (MESH:D012893), Fibrosis (MESH:D005355), Inflammation (MESH:D007249), atrial stretch (MESH:D057896), stage 5 chronic kidney disease (MESH:D051436), apnoeic episode (MESH:C580065), valvular heart disease (MESH:D006349), Diabetes (MESH:D003920), overweight (MESH:D050177), Atrial Cardiomyopathy (MESH:D009202), tachycardia (MESH:D013610), Obesity (MESH:D009765), Hypoxic (MESH:D002534), Arrhythmia (MESH:D001145), Weight gain (MESH:D015430), diastolic dysfunction (MESH:D018487), hypoxia (MESH:D000860), Autonomic Modulation (MESH:C538399), arrhythmic (OMIM:212500), metabolic dysfunction (MESH:D008659), atrial ischemia (MESH:D007511)
- **Chemicals:** Na+ (MESH:D012964), flecainide (MESH:D005424), acarbose (MESH:D020909), -blockers (-), doxazosin (MESH:D017292), lipid (MESH:D008055), TZDs (MESH:D045162), gadolinium (MESH:D005682), ROS (MESH:D017382), glucose (MESH:D005947), amlodipine (MESH:D017311), Alcohol (MESH:D000438), Oxygen (MESH:D010100), chlorthalidone (MESH:D002752), TZD (MESH:C089946), triglycerides (MESH:D014280), losartan (MESH:D019808), lisinopril (MESH:D017706), sulfonylureas (MESH:D013453), biguanides (MESH:D001645), Metformin (MESH:D008687), AGEs (MESH:D017127)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953207/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12953207/full.md

## References

231 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953207/full.md

---
Source: https://tomesphere.com/paper/PMC12953207